London — AstraZeneca said Monday its COVID-19 vaccine provided strong protection against disease and complete protection against hospitalization and death across all age groups in a late-stage U.S. study.
The British drug manufacturer also said its experts didn't identify any safety concerns related to the vaccine, including any surrounding a rare blood clot that was identified in Europe. Scientists found no increased risk of clots among the more than 20,000 people who got at least one dose of the AstraZeneca shot. AstraZeneca said the advanced trial data on the vaccine it developed along with Oxford University shows it is 79% effective. Although the vaccine has been authorized in more than 50 countries, it hasn't been given the green light in the U.S. yet — and has struggled to gain public trust amid a troubled rollout. The U.S. study was made up of 30,000 volunteers, 20,000 of whom were given the vaccine while the rest got placebo shots. The results were announced Monday. In a statement, AstraZeneca said its vaccine had a 79% efficacy rate at preventing symptomatic COVID and was 100% effective in stopping severe disease and hospitalization.
0 Comments
The Indian capital New Delhi will be under a strict lockdown for six days starting on Monday night, the city's Chief Minister Arvind Kejriwal said, adding the healthcare system was at a breaking point because of the worsening COVID-19 outbreak.
The city was also facing acute shortages of hospital beds, medical oxygen supplies and key medicines such as the anti-viral Remdesivir, Kejriwal said. London — AstraZeneca said Monday its COVID-19 vaccine provided strong protection against disease and complete protection against hospitalization and death across all age groups in a late-stage U.S. study.
The British drug manufacturer also said its experts didn't identify any safety concerns related to the vaccine, including any surrounding a rare blood clot that was identified in Europe. Scientists found no increased risk of clots among the more than 20,000 people who got at least one dose of the AstraZeneca shot. AstraZeneca said the advanced trial data on the vaccine it developed along with Oxford University shows it is 79% effective. Although the vaccine has been authorized in more than 50 countries, it hasn't been given the green light in the U.S. yet — and has struggled to gain public trust amid a troubled rollout. The U.S. study was made up of 30,000 volunteers, 20,000 of whom were given the vaccine while the rest got placebo shots. The results were announced Monday. In a statement, AstraZeneca said its vaccine had a 79% efficacy rate at preventing symptomatic COVID and was 100% effective in stopping severe disease and hospitalization. - CBS News |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
February 2022
Categories |